Why Patients Stop Taking Lemborexant for Insomnia

Online Reviews Show High Discontinuation Rates for Lemborexant

About one in four patients taking the insomnia drug lemborexant stopped or planned to stop the medication because of unsettling adverse effects, according to a study published in Sleep Medicine.

Researchers from Rutgers Brain Health Institute, Virginia Commonwealth University, and the University of Sydney examined 260 online reviews submitted between 2020 and 2023. Of those 260 individuals, 70 had stopped taking the prescription sleep aid or intended to discontinue it.

Patient sentiment split sharply between positive and negative extremes. The most frequent rating assigned to the medication was 1 out of 10, followed immediately by 10 out of 10.

Sleep Paralysis and Vivid Dreams Prompt Patient Dropouts

Disturbing nighttime events separated the patients who discontinued lemborexant from those who continued taking it. Sleep paralysis appeared in 40 percent of reviews from people who stopped or planned to stop, compared with 15 percent among the rest of the sample.

Sleep paralysis involves waking up while remaining temporarily unable to move or speak. One reviewer recounted feeling paralyzed and unable to scream before waking a spouse in distress.

Vivid dreams and intense nightmares also appeared across roughly one-third of all patient reviews. Many reviewers identified those vivid nightmares as the explicit reason they could no longer take the drug.

The Biological Mechanism Behind Orexin Blockade and Parasomnias

Blocking wakefulness signals in the brain can alter normal sleep architecture by increasing rapid-eye-movement dreaming sleep. Lemborexant, which received approval from the United States Food and Drug Administration (FDA) in 2019, works by inhibiting orexin, a neurotransmitter that promotes wakefulness.

During standard dreaming sleep, the brain actively shuts down skeletal muscle control to prevent a person from physically acting out dreams. When orexin antagonists prolong or intensify dreaming sleep, that normal muscle inhibition and dream imagery can bleed into conscious waking moments.

The study authors noted that this physiological carryover explains why users experience temporary immobility alongside waking hallucinations.

Discrepancies Between Controlled Trials and Real-World Experience

Patient-reported experiences online diverged substantially from the adverse event rates documented during pre-approval clinical trials. In the primary randomized trials for lemborexant, fewer than two in 100 participants reported sleep paralysis, while one to three in 100 noted abnormal dreams.

Within the online review dataset, two-thirds of all reviewers mentioned at least one side effect, and one in five described sleep paralysis.

The investigators highlighted that online review forums carry clear selection bias. Individuals experiencing either exceptional relief or severe side effects write online reviews far more frequently than patients with unremarkable outcomes.

Considerations for Managing Rest and Sleep Disturbances

Lemborexant provides clear sleep improvements for a portion of users, but outcomes vary widely across individuals. Roughly one-third of the reviewed patients stated the drug meaningfully improved their sleep, while half reported minimal to no benefit.

Nighttime recovery directly influences daytime energy, metabolic regulation, and stress resilience. Anyone experiencing disruptive nightmares, paralysis, or lingering grogginess on sleep medications should consult their prescribing clinician to adjust care.